Exact Mass: 524.3071
Exact Mass Matches: 524.3071
Found 187 metabolites which its exact mass value is equals to given mass value 524.3071
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
VPGPR Enterostatin
Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249) [HMDB] Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249).
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid
2beta,3alpha,14alpha,16-Tetraacetoxy-15beta-hydroxy-ent-pimarane
(1R,3aS,5R,10aS,11aS,13aR)-1,2,3,3a,3b,4,5,5a,6,12,13,13a-dodecahydro-3a,6,6,13a-tetramethyl-1-[(1S)-1-((2S)-5-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-8-oxo-8H-cyclopenta[5,6]cyclopropa[1,8a]naphtho[2,1-c]oxepin-5-yl acetate|schisanbilactone A
16-acetoxy-22alpha-hydroxy-29-nor-24-methylcycloart-1,4, 24(24a)-trien-3,23-dion-3,4-lactone|4-methylene-neomacrolactone
(21R,23S)-3,26-dioxo-21,23:23,26-diepoxylanosta-8,24-dien-21-yl acetate|omphalocarpoidone
24-acetoxy-18alpha-hydroxy-A(1)-norlupa-2,20(29)-diene-27,28-diolic acid 28-methyl ester 27,18alpha-lactone
(1R*,2R*,3E,7R*,11R*,12S*)-2-O-acetyl-16-O-(3-hydroxy-3-methylglutaryl)-dolabella-3,8(17)-dien-2,7,16,18-tetrol
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid_minor
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid_major
Phe Phe Ile Val
Phe Phe Leu Val
Phe Phe Val Ile
Phe Phe Val Leu
Phe Ile Phe Val
Phe Ile Val Phe
Phe Leu Phe Val
Phe Leu Val Phe
Phe Val Phe Ile
Phe Val Phe Leu
Phe Val Ile Phe
Phe Val Leu Phe
His Ile Lys Gln
His Ile Gln Lys
His Lys Ile Gln
His Lys Leu Gln
His Lys Gln Ile
His Lys Gln Leu
His Leu Lys Gln
His Leu Gln Lys
His Gln Ile Lys
His Gln Lys Ile
His Gln Lys Leu
His Gln Leu Lys
Ile Phe Phe Val
Ile Phe Val Phe
Ile His Lys Gln
Ile His Gln Lys
Ile Lys His Gln
Ile Lys Gln His
Ile Gln His Lys
Ile Gln Lys His
Ile Val Phe Phe
Lys His Ile Gln
Lys His Leu Gln
Lys His Gln Ile
Lys His Gln Leu
Lys Ile His Gln
Lys Ile Gln His
Lys Leu His Gln
Lys Leu Gln His
Lys Gln His Ile
Lys Gln His Leu
Lys Gln Ile His
Lys Gln Leu His
Leu Phe Phe Val
Leu Phe Val Phe
Leu His Lys Gln
Leu His Gln Lys
Leu Lys His Gln
Leu Lys Gln His
Leu Gln His Lys
Leu Gln Lys His
Leu Val Phe Phe
Gln His Ile Lys
Gln His Lys Ile
Gln His Lys Leu
Gln His Leu Lys
Gln Ile His Lys
Gln Ile Lys His
Gln Lys His Ile
Gln Lys His Leu
Gln Lys Ile His
Gln Lys Leu His
Gln Leu His Lys
Gln Leu Lys His
Val Phe Phe Ile
Val Phe Phe Leu
Val Phe Ile Phe
Val Phe Leu Phe
Val Ile Phe Phe
Val Leu Phe Phe
22-[(2R)-1-hydroxy-3-phosphonooxypropan-2-yl]oxy-22-oxodocosanoic acid
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-3-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
1-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-3-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
1-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
1-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
1-(9Z-nonadecenoyl)-glycero-3-phospho-(1-sn-glycerol)
21-hydroxy-4-(hydroxymethyl)-3-(2-hydroxypropyl)-6,10,16,20-tetramethyl-24-oxapentacyclo[20.2.1.0¹,⁶.0¹¹,²⁰.0¹⁴,¹⁹]pentacosa-4,8,12,21-tetraene-23,25-dione
(6r)-6-[(1r,2s,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7,10-dioxo-1h,2h,3h,4h,5h,5ah,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid
2-hydroxy-2,4-dimethyl-5-[(5e,7e,9e,11e)-2,4,14-trihydroxy-9,13,15-trimethyl-17-phenylheptadeca-5,7,9,11-tetraen-1-yl]furan-3-one
2-{[(2s)-2-{[(2r)-2-[(2s,3r)-2-amino-n,3-dimethylpentanamido]-1-hydroxy-3-phenylpropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}benzoic acid
(3s)-5-{[(1r,3as,4s,9r,12as)-4-(acetyloxy)-9-hydroxy-1-(2-hydroxypropan-2-yl)-3a-methyl-10-methylidene-1h,2h,3h,4h,7h,8h,9h,11h,12h,12ah-cyclopenta[11]annulen-6-yl]methoxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
methyl 8-{[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-5-(3-hydroxy-3-methylpent-4-en-1-yl)-1,4a,6-trimethyl-2,3,4,5,8,8a-hexahydronaphthalene-1-carboxylate
bisacutifolone c
{"Ingredient_id": "HBIN018600","Ingredient_name": "bisacutifolone c","Alias": "NA","Ingredient_formula": "C32H44O6","Ingredient_Smile": "CC1CCC2(C1(C(=O)C=C(C2C)C3CCCC4=C3C(=O)C5(C(CCC5(C4C)C)C)C(=O)OC)C(=O)OC)C","Ingredient_weight": "524.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2434","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15479053","DrugBank_id": "NA"}